Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | FLT1 | P17948 | 3/20 | 0.40 |
| ▸ | FLT4 | P35916 | 3/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 7/20 | 0.39 |
| ▸ | BCR | P11274 | 5/20 | 0.39 |
| ▸ | ABL2 | P42684 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2348180 | 0.91 | ALOX5 (0.44) | EGFRPRKCAPDGFRBPDGFRAKIT | |
| SCHEMBL4597593 | 0.84 | ALOX5 (0.41) | EGFRPRKCAKITKDRFLT1 | |
| SCHEMBL2344918 | 0.84 | EGFR (0.42) | EGFRPRKCAPDGFRBPDGFRAKIT | |
| SCHEMBL10033774 | 0.83 | ALOX5 (0.43) | EGFRPRKCAPDGFRBPDGFRAKIT | |
| SCHEMBL2341833 | 0.80 | FLT1 (0.44) | EGFRPRKCAKITKDRFLT1 | |
| SCHEMBL543764 | 0.78 | ABL1 (0.55) | EGFRPRKCAPDGFRBPDGFRAKIT | |
| SCHEMBL2828935 | 0.77 | KIT (0.47) | PDGFRBPDGFRAKITKDRFLT1 | |
| SCHEMBL543648 | 0.76 | PORCN (0.49) | EGFRPRKCAPDGFRBPDGFRAKIT | |
| SCHEMBL543943 | 0.76 | ABL1 (0.45) | PDGFRBPDGFRAKITKDRFLT1 | |
| SCHEMBL2346522 | 0.73 | ALOX5 (0.48) | KITKDRFLT1FLT4ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108616-A1 | SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AB SCIENCE | 2012-05-03 | — | — | US | disclosed |
| US-20120108616-A1 | SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AB SCIENCE | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108616-A1 | SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | KIT, FLT3, LTK | EGFR 289/4885PRKCA 361/4885PDGFRB 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.